© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
March 22, 2010
"Statin" (HMG CoA reductase inhibitors, used for dyslipidemia) use in the US is very high and climbing. As the population becomes fatter and even some children become extremely obese, these agents are often prescribed to address elevated LDL and other lipid perturbations.
March 15, 2010
Carbamazepine has long been a mainstay of epilepsy pharmacotherapy. However, this agent is not without problems, such as significant rashes and strong hepatic enzyme induction.
February 24, 2010
Until just a few years ago, neurologists could only observe as MS ravaged the nervous systems of our patients. The therapies available were basically symptomatic, and didn't really alter prognosis. The advent of disease modifying therapies (DMT) made a big difference: These immune system modifying agents slowed the progression of MS and improved quality of life for many patients.
January 28, 2010
AEDs are the mainstay of the treatment of epilepsy. A large number of new drugs have become available in the last two decades. These newer agents generally offer a better adverse effect profile and fewer drug-drug interactions compared with the older drugs. Efficacy, however, may not be much better.